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PCLINICAL RESEARCH Coronary Artery Disease
Disease Progression in
Nonintervened Saphenous Vein Graft Segments
A Serial Intravascular Ultrasound Analysis
Young Joon Hong, MD,* Gary S. Mintz, MD,† Sang Wook Kim, MD,* Sung Yun Lee, MD,*
Seok Yeon Kim, MD,* Teruo Okabe, MD,* Augusto D. Pichard, MD,* Lowell F. Satler, MD,*
Ron Waksman, MD,* Kenneth M. Kent, MD, PHD,* William O. Suddath, MD,*
Neil J. Weissman, MD*
Washington, DC; and New York, New York
Objectives We used serial intravascular ultrasound (IVUS) to assess disease progression in nonintervened saphenous vein
graft (SVG) segments to determine the natural rate of disease progression in SVG.
Background There are no serial IVUS studies of disease progression or luminal compromise in SVGs.
Methods We assessed serial (baseline and follow-up at 16.2  7.4 months) IVUS findings in 50 nonintervened SVG seg-
ments in 44 patients. The SVG age was 13.5  3.6 years.
Results Overall, from baseline to follow-up, plaque area increased (  0.58  1.25 mm2, p  0.003), and SVG and
minimum lumen area (MLA) decreased (  0.50  1.14 mm2, p  0.002, and   1.08  1.28 mm2,
p  0.001, respectively). The MLA decreased in 34 lesions (  1.67  1.08 mm2), and MLA increased in 16
lesions (  0.19  0.47 mm2). Compared with lesions with an increase in MLA, lesions with a decrease in
MLA were associated with: 1) larger baseline SVG and plaque areas and plaque burden (15.57  3.90 mm2 vs.
11.55  2.30 mm2, p  0.001; 7.97  3.77 mm2 vs. 4.27  1.92 mm2, p  0.001; and 48.7  14.2% vs.
36.0  13.4%, p  0.004, respectively); and 2) a greater decrease in SVG area (  0.96  1.05 mm2 vs.
0.48  0.58 mm2, p  0.001) and greater increase in plaque area (  0.71  1.47 mm2 vs. 0.29  0.45
mm2, p  0.001). The MLA correlated with both plaque area (r  0.589, p  0.001) and SVG area (r  0.470,
p  0.001), and plaque area correlated with SVG area (r  0.436, p  0.002). There were linear relations be-
tween both the plaque area (r  0.519, p  0.001) and lumen area (r  0.500, p  0.001) versus follow-up
low-density lipoprotein (LDL) cholesterol; a follow-up LDL cholesterol of 100 mg/dl predicted no plaque increase.
Conclusions Lumen loss in nonintervened SVG segments correlated with an increase in plaque area and a decrease in SVG
area (plaque growth and negative remodeling) with a linear relationship between plaque growth versus follow-up
LDL cholesterol leading to long-term lumen loss. (J Am Coll Cardiol 2009;53:1257–64) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.048i
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wtherosclerosis imaging has contributed to the understand-
ng of the natural history of coronary artery disease, includ-
ng the processes leading to luminal narrowing and the
ssessment of disease burden and therapeutic efficacy. Serial
ntravascular ultrasound (IVUS) is now being used to study
laque progression and regression (1–13), in part because of
uccessful studies of restenosis and transplant vasculopathy.
ith IVUS, changes in lumen dimensions in non-
rom the *Cardiovascular Research Institute/Medstar Research Institute, Washing-
on Hospital Center, Washington, DC; and the †Cardiovascular Research Founda-
ion, New York, New York. Dr. Mintz has served as consultant to and held equity in
olcano, and has received honoraria from Boston Scientific.i
Manuscript received August 18, 2008; revised manuscript received December 2,
008, accepted December 15, 2008.ntervened segments in native coronary arteries can be
eparated into an increase or decrease in vessel area and/or
n increase or decrease in plaque area (1–8,14–19). How-
ver, to the best of our knowledge, no studies have examined
isease progression or luminal compromise in non-
ntervened saphenous vein bypass graft (SVG) lesions.
herefore, the purpose of the present study was to use serial
baseline and follow-up) IVUS to assess disease progression
n nonintervened SVG segments.
ethods
atient population. We identified 44 patients who under-
ent baseline and follow-up IVUS imaging of a non-ntervened SVG segment at the Washington Hospital
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had a minimum lumen area
(MLA) 4.0 mm2 and a plaque
burden 0.75 and were not
treated with percutaneous coro-
nary intervention. Hospital re-
cords of all the patients were
reviewed to obtain information
on clinical demographic data and
medical history. This study was
performed with the approval of
the institutional review board.
VUS imaging and analysis. The IVUS examinations were
erformed at baseline and at follow-up after intra-SVG
dministration of 200 g nitroglycerin with a commercially
vailable IVUS system (Boston Scientific Corporation/
CIMed, Minneapolis, Minnesota). The IVUS catheter
as advanced distal to the target lesion, and imaging was
erformed retrograde to the aorto-ostial junction at an
utomatic pullback speed of 0.5 mm/s.
The IVUS analyses were performed according to the
merican College of Cardiology Clinical Expert Consensus
ocument on Standards for Acquisition, Measurement and
eporting of Intravascular Ultrasound Studies (20). Quan-
itative IVUS measurements were performed with planim-
try software (TapeMeasure, INDEC Systems Inc., Moun-
ain View, California) and included SVG area, lumen area,
laque (SVG – lumen) area, and plaque burden (plaque
rea/SVG area). The same anatomic image slices were
nalyzed at baseline and at follow-up using axial landmarks
nd the known pullback speed of the transducer. The
natomic image slices selected for serial analysis had an axial
ocation at the smallest follow-up MLA site and at the
ollow-up proximal and distal reference segments (single
lices with the largest lumen and smallest plaque burden
ithin 10 mm proximally and distally to the follow-up
LA site but before any large side branch). Soft plaque was
ess bright than the adventitia, fibrotic plaque was as bright
s or brighter than the adventitia without acoustic shadow-
ng, and calcific plaque was brighter than the adventitia with
coustic shadowing. When there was no dominant plaque
omposition, the plaque was classified as mixed. Remodel-
ng index was the ratio of the lesion site SVG cross-sectional
rea divided by the average of the proximal and distal
eference SVG cross-sectional area (21).
tatistical analysis. The Statistical Package for Social Sci-
nces for Windows version 15.0 (SPSS Inc., Chicago,
llinois) was used for all analyses. Continuous variables were
resented as the mean value  1 SD and compared by
aired or unpaired Student t test or nonparametric Wil-
oxon signed-rank test if normality assumption was vio-
ated. Discrete variables are presented as percentages and
elative frequencies. Linear regression analysis was used
o evaluate the associations among lumen area versus
laque area and SVG area, between SVG area versus
Abbreviations
and Acronyms
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
MLA  minimum lumen
area
SVG  saphenous vein
graftlaque area, and between plaque area and lumen area
a
Rersus follow-up low-density lipoprotein (LDL) choles-
erol. All analysis was done on an SVG level and not a
atient level. A value of p  0.05 was considered
tatistically significant.
esults
aseline characteristics. Baseline characteristics are sum-
arized in Table 1. The SVG age was 13.5 3.6 years, and
he interval between IVUS studies was 16.2  7.4 months.
ne-third of the patients had diabetes mellitus, more than
wo-thirds of the patients had hypertension, and more than
wo-thirds of the patients took statins.
erial IVUS results. Serial IVUS results are shown in
able 2. From baseline to follow-up, reference segment
laque area increased and SVG and lumen areas decreased.
rom baseline to follow-up, lesion site plaque area increased
  0.58  1.25 mm2) and SVG and lumen areas
ecreased (  0.50  1.14 mm2 and   1.08  1.28
m2, respectively). The remodeling index also decreased
rom baseline to follow-up, but plaque morphology did not
hange. The lumen area correlated with both plaque area
r  0.589, p  0.001) and SVG area (r  0.470, p 
.001), and plaque area correlated with SVG area (r 
.436, p 0.002) (Fig. 1). When patients were divided into
groups according to a follow-up duration 12 and 12
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Time of follow-up (months) 16.2  7.4
Graft age (yrs) 13.5  3.6
Age (yrs) 64.5  12.8
Male 34 (77.3)
Clinical presentation
Stable angina 8 (18.2)
Unstable angina 32 (72.7)
NSTEMI 4 (9.1)
Diabetes mellitus 14 (31.8)
Hypertension 30 (68.2)
Smoking 13 (29.5)
Family history of coronary artery disease 10 (22.7)
Left ventricular ejection fraction (%) 39  15
Total cholesterol (mg/dl) 203  128
LDL cholesterol (mg/dl) 126  39
HDL cholesterol (mg/dl) 39  15
Triglycerides (mg/dl) 184  120
Medications
Statins 34 (77.3)
Beta-blockers 33 (75.0)
Angiotensin-receptor antagonists 24 (54.5)
Clopidogrel 44 (100.0)
Diseased vessel (n  50)
SVG to LAD 13 (26.0)
SVG to LCX 21 (42.0)
SVG to RCA 16 (32.0)
ata are presented as n (%) of patients or mean  SD.
HDL  high-density lipoprotein; LAD  left anterior descending artery; LCX  left circumflex
rtery; LDL  low-density lipoprotein; NSTEMI  non–ST-segment elevation myocardial infarction;
CA  right coronary artery.
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April 14, 2009:1257–64 SVG Disease Progressiononths, there were no significant differences in plaque
rea and plaque burden between lesions with a follow-up
uration 12 months (14 to 25 months, n  29) and lesions
ith a follow-up duration 12 months (2 to 11 months, n 
1) (  0.66  1.43 mm2 vs.   0.52  0.99 mm2, p
0.322; and   7.6  7.7% vs.   4.5  7.3%, p 
.160, respectively).
ifferences between lesions with a decrease in MLA and
hose with an increase in MLA. We analyzed the cross-
ection located at the follow-up MLA site. The MLA
ecreased in 34 lesions (mean   1.67  1.08 mm2),
nd MLA increased in 16 lesions (mean   0.19  0.47
m2). Baseline clinical characteristics according to an in-
rease versus a decrease in MLA are shown in Table 3.
ther than male predominance and a trend toward more
nstable clinical presentation in lesions with a decrease in
LA, there were no differences between the 2 groups.
Baseline and follow-up IVUS findings according to an
ncrease versus a decrease in MLA are shown in Table 4.
ompared with lesions with an increase in MLA at follow-
p, lesions with a decrease in MLA were associated with
arger baseline SVG and plaque areas and plaque burden
nd with a greater decrease in SVG area and a greater
ncrease in plaque area during follow-up.
elationship between plaque area and lumen area
ersus follow-up LDL cholesterol. There were linear
elations between both plaque area (r  0.519, p  0.001)
nd lumen area (r  0.500, p  0.001) versus follow-up
DL cholesterol. With regression analysis, the cutoff value
f follow-up LDL cholesterol that best predicted no plaque
rea increase was 100 mg/dl (Fig. 2).
When patients were divided into 2 groups according to
ollow-up LDL cholesterol above and below 100 mg/dl,
here were no significant differences in the baseline IVUS
erial Intravascular Ultrasound Data
Table 2 Serial Intravascular Ultrasound Data
Baseline Follow-Up p Value
Reference
SVG area (mm2) 14.02 3.68 13.68 3.37 0.023
Lumen area (mm2) 9.45 2.59 8.56 2.23 0.008
Plaque area (mm2) 4.57 1.66 5.12 2.18 0.016
Plaque burden (%) 32.6 13.8 37.4 11.2 0.012
Smallest follow-up MLA site
SVG area (mm2) 14.28 3.93 13.78 3.37 0.003
Lumen area (mm2) 7.50 1.65 6.42 2.04 0.001
Plaque area (mm2) 6.79 3.71 7.37 3.70 0.002
Plaque burden (%) 44.6 15.1 50.9 17.7 0.001
Remodeling index 1.019 0.286 1.007 0.128 0.032
Plaque morphology 0.12
Soft 34 (68) 29 (58)
Fibrotic 10 (20) 15 (30)
Calcific 4 (8) 5 (10)
Mixed 2 (4) 1 (2)
ata are presented as n (%) of patients or mean  SD.
MLA  minimum lumen area; SVG  saphenous vein graft.ariables between lesions with follow-up LDL cholesterolFigure 1 IVUS Measurement Correlations
The correlation between lumen area versus plaque area (A), between
lumen area versus saphenous vein graft (SVG) area (B), and between SVG
area versus plaque area (C).
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SVG Disease Progression April 14, 2009:1257–64100 mg/dl (n  31) and lesions with follow-up LDL
holesterol 100 mg/dl (n  19) (Table 5). Lesions with
ollow-up LDL cholesterol 100 mg/dl had a greater
ncrease in plaque area and a greater decrease in lumen area
ompared with lesions with follow-up LDL cholesterol
100 mg/dl at follow-up (Fig. 3). Plaque regressed in 13
esions (26% of the lesions) at follow-up, and this plaque
egression was observed more frequently in lesions with
ollow-up LDL cholesterol 100 mg/dl compared with
esions with follow-up LDL cholesterol 100 mg/dl
63.2% vs. 16.1%, p  0.001).
Baseline Clinical Characteristics According to In
Table 3 Baseline Clinical Characteristics Ac
Decre
(
Time of follow-up (months) 16
Graft age (yrs) 13
Age (yrs) 65
Male 2
Clinical presentation
Stable angina
Unstable angina 2
NSTEMI
Diabetes mellitus 2
Hypertension 2
Smoking 1
Family history of coronary artery disease
Left ventricular ejection fraction (%) 3
Total cholesterol (mg/dl) 20
LDL cholesterol (mg/dl) 13
HDL cholesterol (mg/dl) 3
Triglycerides (mg/dl) 18
Diseased vessel
SVG to LAD
SVG to LCX 1
SVG to RCA 1
Data are presented as n (%) of patients or mean  SD.
Abbreviations as in Tables 1 and 2.
aseline and Follow-Up Intravascular Ultrasoundindings According to Incre se/Dec ease in MLA
Table 4 Baseline and Follow-Up Intravascular UltrasoundFindings According to Increase/Decrease in MLA
Decrease in MLA
(n  34)
Increase in MLA
(n  16)
p
Value
Baseline SVG area (mm2) 15.57 3.90 11.55 2.30 0.001
Baseline MLA (mm2) 7.60 1.56 7.28 1.85 0.524
Baseline plaque area (mm2) 7.97 3.77 4.27 1.92 0.001
Baseline plaque burden (%) 48.7 14.2 36.0 13.4 0.004
Follow-up SVG area (mm2) 14.61 3.46 12.03 2.44 0.004
Follow-up MLA (mm2) 5.93 1.84 7.47 2.10 0.011
Follow-up plaque area (mm2) 8.69 3.59 4.56 2.01 0.001
Follow-up plaque burden (%) 57.5 15.4 37.0 14.0 0.001
SVG area (mm2) 0.96 1.05 0.48 0.58 0.001
MLA (mm2) 1.67 1.08 0.19 0.47 0.001
plaque area (mm2) 0.71 1.47 0.29 0.45 0.001
plaque burden (%) 8.8 8.0 1.1 2.9 0.001ata are presented as mean  SD.
Abbreviations as in Table 2.When patients were divided into 2 groups according to
tatin therapy, there were no significant differences in the
aseline IVUS variables between statin-treated lesions (n 
0) and nonstatin-treated lesions (n  10) (Table 5), but
here was a smaller increase in plaque area in statin-treated
esions compared with nonstatin-treated lesions. The SVG
rea decreased (negative remodeling) in both statin-treated
Figure 2 Effect of LDL Cholesterol
Changes of saphenous vein graft (SVG) area, lumen area, and plaque area in
lesions with low-density lipoprotein (LDL) cholesterol 100 mg/dl versus
lesions with LDL cholesterol 100 mg/dl.
se/Decrease in MLA
ing to Increase/Decrease in MLA
MLA
)
Increase in MLA
(n  16) p Value
.2 15.8  7.0 0.2
.9 13.3  3.0 0.2
3.3 63.6  10.2 0.2
3) 9 (56.3) 0.025
0.080
7) 4 (25.0)
4) 9 (56.3)
) 3 (18.8)
6) 9 (56.3) 0.3
6) 9 (56.3) 0.3
4) 2 (12.5) 0.14
5) 3 (18.8) 0.7
5 39  15
36 188  112 0.2
1 125  28 0.4
4 40  17 0.4
26 180  115 0.3
0.11
6) 7 (43.8)
0) 4 (25.0)
4) 5 (31.3)crea
cord
ase in
n  34
.6  8
.8  3
.5  1
9 (85.
5 (14.
8 (82.
1 (2.9
4 (70.
4 (70.
1 (32.
8 (23.
9  1
9  1
0  4
8  1
8  1
6 (17.
7 (50.
1 (32.
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Data are presented as mean  SD.
Abbreviations as in Tables 1 and 2.
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April 14, 2009:1257–64 SVG Disease Progressionnd nonstatin-treated lesions; however, this was not statis-
ically significant between statin-treated and nonstatin-
reated lesions (Fig. 4). There were no differences in
laque area change, lumen area change, and SVG area
hange according to type of statin. When we compared
he plaque area change, lumen area change, and SVG area
hange according to the dose of statin (high-dose group
n  18, 60 to 80 mg/day] vs. usual dose group [n  32,
40 mg/day]), plaque area decreased in the high-dose
roup and increased in the usual-dose group (0.23 
.15 mm2 vs. 1.03  1.35 mm2, p  0.001). Plaque
egression was observed more frequently in the high-dose
roup compared with usual-dose group (55.6% vs. 9.4%,
 0.001).
There were no associations between plaque area and
ollow-up high-density lipoprotein cholesterol (p  0.6),
iabetes mellitus (p  0.3), or hypertension (p  0.3).
Figure 4 Effect of Statin Use
Changes of saphenous vein graft (SVG) area,
lumen area, and plaque area according to the statin therapy.
toapy
gs According to
d Statin Therapy
l Follow-Up LDL Cholesterol
<100 mg/dl (n  19) p Value
13.82 4.72 0.548
6.96 1.17 0.073
6.85 4.27 0.930
45.2 15.0 0.825
No Statin (n  10) p Value
14.17 3.97 0.917
7.53 0.71 0.902
6.63 3.90 0.885
42.6 17.3 0.646Figure 3 Correlation With LDL Cholesterol
The correlation between plaque area and low-density lipoprotein
(LDL) cholesterol (A) and between lumen area and LDL cholesterol (B).Baseline Intravascular Ultrasound Findings Accordingthe Follow-Up LDL Cholesterol Levels a d Statin Ther
Table 5 Baseline Intravascular Ultrasound Findinthe Follow-Up LDL Cholesterol Levels an
Follow-Up LDL Cholestero
>100 mg/dl (n  31)
Baseline SVG area (mm2) 14.57 3.41
Baseline MLA (mm2) 7.82 1.82
Baseline plaque area (mm2) 6.75 3.39
Baseline plaque burden (%) 44.3 15.3
Statin (n  40)
Baseline SVG area (mm2) 14.31 3.97
Baseline MLA (mm2) 7.49 1.81
Baseline plaque area (mm2) 6.83 3.71
Baseline plaque burden (%) 45.1 14.7
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he present serial IVUS study of nonintervened SVG
egments showed the following: 1) plaque area increased,
nd SVG and lumen area decreased from baseline to
ollow-up; 2) lesions with a decrease in MLA at follow-up
ere associated with larger baseline SVG and plaque areas
nd with a greater decrease in SVG area and a greater
ncrease in plaque area during follow-up; 3) change in
umen area correlated with both changes in plaque area and
VG area; 4) change in plaque area correlated with a change
n SVG area; 5) there were linear relations between both
hanges in the plaque area and lumen area versus follow-up
DL cholesterol with a cutoff value of follow-up LDL
holesterol of 100 mg/dl predicting no plaque area increase;
nd 6) there was a smaller increase in plaque area in
tatin-treated lesions compared with nonstatin-treated le-
ions. These findings are remarkably similar to serial IVUS
ndings in native coronary arteries.
Serial angiography has been used to study SVG disease
rogression. Rodes-Cabau et al. (22) reported that signifi-
ant angiographic disease progression occurred in 48% of
VG lesions. Domanski et al. (23) reported that the severity
f the SVG stenosis and the size of the SVG lumen
iameter at baseline angiography were predictive of angio-
raphic SVG atherosclerosis progression. Campos et al. (24)
resented long-term follow-up data of normal and mini-
ally diseased SVGs; more than one-half of these grafts
emained normal or minimally diseased at follow-up. Mehta
t al. (25) also showed a favorable outcome if SVGs were
ormal at baseline.
Compared with IVUS—which provides a tomographic,
ransmural view and can directly visualize and measure
therosclerotic plaque—angiography visualizes only lumen
imension and can only indirectly estimate the severity of
therosclerotic plaque. In angiographically normal SVGs,
VUS and pathological studies have shown a doubling of
ntimal thickness (26) and total wall thickness (27) by the
nd of the first post-operative year. However, to date (and
nlike native coronary artery disease) there have been no
ublished serial IVUS data on SVG disease progression
nd, especially, the relationship between progression and
aseline findings. In the current study lumen area
orrelated almost equally with SVG and plaque areas,
hereas in native coronary arteries lumen area corre-
ated more with external elastic membrane area than
ith plaque area.
In transplant studies, changes in plaque burden and
emodeling response were time-dependent. With multi-
lice computed tomography angiography, Lau et al. (28)
eported that lumen loss in SVG between post-operative
onths 1 and 12 is predominantly caused by negative
emodeling of the whole vessel rather than by changes in
all thickness. Tsutsui et al. (11) compared the late disease
rocess of transplant vasculopathy between coronary seg-
ents with early constrictive and expansive remodeling. In (heir study (11), annual changes in intimal area were similar
etween segments with early constrictive remodeling and
xpansive remodeling throughout the follow-up period;
owever, during the second and third year, annual increases
n external elastic membrane area were greater in segments
ith early constrictive remodeling than in segments with
arly expansive remodeling. Despite this late expansion,
egments with early constrictive remodeling showed a cu-
ulative decrease in the external elastic membrane area and
greater lumen loss than segments with early expansive
emodeling. In the present study, which enrolled small
umbers of patients with short follow-up duration, the
rafts were approximately 1 decade old and were imaged
pproximately 16 months apart, and there were no signifi-
ant differences in plaque area change and plaque burden
hange between lesions with a follow-up duration 12
onths and lesions with a follow-up duration 12 months.
ptimally, serial studies of bypass grafts with IVUS imag-
ng at more than 2 time points would provide further
nsight.
mpact of statin therapy and serum follow-up LDL
holesterol on disease progression. Serial IVUS studies
ave been used to evaluate the effect of pharmacology on
laque progression or regression in native coronary arter-
es (29 –38). In the present study, there was a smaller
ncrease in SVG plaque area in statin-treated lesions
ompared with nonstatin-treated lesions, similar to find-
ngs in native coronary arteries. Serial IVUS studies have
lso been used to study the relationship between plaque
rogression or regression in native coronary arteries and
erum LDL cholesterol levels (14,30,32–38). In these stud-
es, the cutoff value of LDL cholesterol that was associated
ith either no change or a decrease in plaque area was100
g/dl. The results of the present study were similar to those
f the previous studies in native coronary arteries
14,30,33–38).
Angiographic but not IVUS studies have reported the
elationship of statin therapy and lipid-lowering on athero-
clerosis progression in SVGs. The Post-CABG (Post
oronary Artery Bypass Graft) trial investigators (39) re-
orted that 27% of patients treated with an aggressive LDL
holesterol-lowering regimen had SVG disease progres-
ion versus 39% of patients treated with a moderate LDL
holesterol-lowering regimen. Goldman et al. (40) re-
orted that lower serum cholesterol was a significant
redictor of graft patency in the VA Cooperative Studies
rial. Domanski et al. (23) reported that high LDL
holesterol was an independent predictor for SVG ath-
rosclerosis progression in the CABG trial. Rodes-Cabau
t al. (22) reported that low high-density lipoprotein
holesterol was associated with SVG atherosclerosis pro-
ression. Knatterud et al. (41) reported a 24% reduction
n composite clinical end points in patients assigned to an
ggressive strategy (LDL cholesterol levels 100 mg/dl)
ompared with patients assigned to a moderate strategy
LDL cholesterol levels 132 to 136 mg/dl) during 7.5
y
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April 14, 2009:1257–64 SVG Disease Progressionears of follow-up in the CABG trial. In the present
tudy there was a linear relationship between the change
f plaque area versus follow-up LDL cholesterol; the
utoff value of follow-up LDL cholesterol of 100 mg/dl
as associated with no plaque area increase with a trend
oward less progression in statin-treated patients. Our
esults also suggest that serial IVUS study can be used to
valuate SVG progression/regression and assess the ef-
ects of pharmacotherapy and risk factors, which is
imilar to findings in native coronary arteries.
emodeling. With IVUS, remodeling can be assessed both
t a single time point and serially. At a single time point, the
emodeling index is derived by comparing lesion vessel
ross-sectional area with the reference (42). With serial
VUS examinations, remodeling can be assessed as the
ncrease or decrease in vessel area; positive serial remodeling
an be defined as an increase of vessel area; in contrast,
egative or intermediate serial remodeling can be defined as
decrease or no change of vessel area (18,19).
Remodeling is a well-established phenomenon in native
oronary arteries; however, the presence of remodeling
ithin SVGs is controversial. Nishioka et al. (43) reported
lack of remodeling in SVGs; however, this conclusion was
isputed by other authors (44–46). In the present serial
VUS study, lumen loss in nonintervened SVG segments
as associated with negative remodeling (decrease in SVG
rea) from baseline to follow-up; furthermore, the change in
VG area correlated with the change in plaque area. Again,
hese results are remarkably similar to those in native
oronary arteries and indicate that SVGs undergo remod-
ling just like native arteries.
tudy limitations. First, this study is based on a small
ample size, was retrospective, and was from a single center.
econd, we were able to include only patients with signifi-
ant SVG disease who were admitted for repeat cardiac
evascularization and not patients soon after surgery. There-
ore, the findings of the present study might not be
pplicable to the general population. Third, the present
tudy is based on the serial comparison of measurements in
ingle-image slices, an approach validated in many initial
VUS studies. However, because of limitations of matching,
ome studies use volumetric analysis by integrating several
lices along entire coronary segments. Fourth, plaque mor-
hology was assessed visually with grayscale IVUS; however,
his conventional IVUS has significant limitations in assess-
ng plaque composition. At present, radiofrequency analysis
as become available for further plaque characterization but
as not yet been validated in SVGs. Fifth, our mean
ollow-up period was only 16 months, and we did not
ollect longer-term IVUS follow-up data. Lastly, the pop-
lation was a relatively high-risk group (prevalence of
iabetes mellitus at 31.8% and left ventricular ejection
raction at 39%), so the results should only be applied to the
opulation studied.
1onclusions
umen loss in nonintervened SVG segments was associated
ith an increase in plaque area and a decrease in SVG area
plaque growth and negative remodeling). Importantly,
here was a linear relationship between follow-up LDL
holesterol and plaque growth leading to lumen loss during
ollow-up.
eprint requests and correspondence: Dr. Neil J. Weissman,
ashington Hospital Center, 100 Irving Street, Northwest, Suite
B-5123, Washington, DC 20010. E-mail: Neil.J.Weissman@
edstar.net.
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